JUN 24, 2020 1:45 PM PDT

Gilead to Test Inhalable Remdesivir Against COVID-19

WRITTEN BY: Annie Lennon

Gilead has announced that it will soon start trials for an inhalable form of Remdesivir, the first drug to receive Emergency Use Authorization by the FDA to treat COVID-19.

Currently, Remdesivir is administered to patients intravenously. This means that it can only be used in clinical settings under medical supervision.

The new, inhalable version of the treatment could change this. To be administered via nebulizer, a device commonly used to treat asthma, Gilead hopes that the more convenient treatment will be used by patients at multiple stages of infection as opposed to just severe stages demanding hospitalization. 

 “Pretty much every outpatient urgent care clinic has them. You could potentially treat somebody on the spot who has a positive test” for the coronavirus “but may or may not have symptoms.” says Dr. Angela Rasmussen, a virologist at Columbia University. 

Starting this week, healthy volunteers will be screened for Phase I trials of the inhalable treatment to check its safety. If all goes to plan, patients infected with COVID-19 may then be able to begin trials with the treatment from August. 

As antivirals are thought to be most effective during the early stages of infection, Gilead hopes that the convenience of administering the drug via nebulizer may mean it can curb the virus earlier on. 

“If you could get rid of the virus before they develop those disease symptoms, you would probably have better clinical outcomes across many patients,” says Dr. Rasmussen.

Although nebulizers generally pose few problems to patients, they have been known to irritate some people’s airways. Moreover, previous experiments for nebulizer treatments for gene therapy and insulin have both failed. There is thus no guarantee that inhalable Remdesivir will work. 

Regardless of whether it works, Gilead plans on producing two million courses of Remdesivir by the end of the year. The company has also stated that it hopes to combine the antiviral with other drugs to enhance its effects. 


Sources: Medical Xpress, New York Times, Fierce Pharma

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
NOV 01, 2020
Cannabis Sciences
Can Cannabis Treat ALS?
NOV 01, 2020
Can Cannabis Treat ALS?
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative illness that damages motor neurons and leads to progressive m ...
NOV 08, 2020
Drug Discovery & Development
Psychedelic Mushrooms Effectively Treat Major Depression
NOV 08, 2020
Psychedelic Mushrooms Effectively Treat Major Depression
Over 17 million people in the US and 300 million people worldwide are estimated to have experienced major depression. No ...
DEC 17, 2020
Genetics & Genomics
Using Tomatoes to Produce a Parkinson's Drug
DEC 17, 2020
Using Tomatoes to Produce a Parkinson's Drug
More and more people are being diagnosed with Parkinson's disease as the world's population ages. Scientists have now en ...
DEC 24, 2020
Drug Discovery & Development
New Gene Therapy Targets Deafness
DEC 24, 2020
New Gene Therapy Targets Deafness
New gene therapy study addresses treatment methods for deafness. "In this study we focused on genetic deafness caus ...
JAN 09, 2021
Drug Discovery & Development
Anticoagulant Drugs Prevent Cancer Spreading to Brain
JAN 09, 2021
Anticoagulant Drugs Prevent Cancer Spreading to Brain
Researchers from the Heidelberg University in Germany have found that anticoagulant drugs that inhibit thrombin (an enzy ...
JAN 13, 2021
Immunology
Antibodies Gain the Upper Hand Against Sly Tumors
JAN 13, 2021
Antibodies Gain the Upper Hand Against Sly Tumors
Tumors use ingenious approaches to stay just out of reach of immune cells on patrol and avoid detection. Indeed, cancer ...
Loading Comments...